Skip to content

Omega 3 in the management of breast cancer patients

Omega 3 in the management of mood and sleep changes complication due to hormonal therapy in breast cancer patients:

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180722040556N6
Enrollment
60
Registered
2021-03-01
Start date
2020-05-18
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group: Intervention group: Administration of 1 g capsule of omega 3 provided by Zahravi pharmaceutical Company, 2 g daily (twice a day orally) for 4 weeks and then baselin

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult women suffering from hormone-positive breast cancer with grade I to III who are receiving Selective estrogen receptor modulators (SERM) or Aromatase inhibitors (AIs) family drug. Patients who are complaining from hot flash ( at least 4 times in a previous month) Patients who have compliance and ability to take omega3 orally

Exclusion criteria

Exclusion criteria: Patients who are in metastatic stage . Patients who have a history of other malignancies except for breast cancer. Patients who are receiving antipsychotic, anti-depression, anti-anxiolytic, sedative or hypnotic or anti-epileptic drugs. Patients with a history of hypersensitivity reaction to omega 3 .

Design outcomes

Primary

MeasureTime frame
The amount and severity of hot flash. Timepoint: Before intervention and 4 weeks. Method of measurement: Menopause Rating Scale (MRS) questionnaire.

Secondary

MeasureTime frame
Sexual function. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Female Sexual Function Index questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Moghaddas

Esfahan University of Medical Sciences

azadeh_moghaddas@yahoo.com+98 31 3792 7074

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026